Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors

Am J Cardiol. 2002 Apr 15;89(8):976-9. doi: 10.1016/s0002-9149(02)02251-8.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abciximab
  • Aged
  • Antibodies, Monoclonal / therapeutic use
  • Cardiac Catheterization
  • Coronary Disease / epidemiology
  • Coronary Disease / therapy*
  • Eptifibatide
  • Female
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Male
  • Middle Aged
  • Peptides / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Sex Factors
  • Stents*
  • Tirofiban
  • Treatment Outcome
  • Tyrosine / analogs & derivatives*
  • Tyrosine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Tyrosine
  • Tirofiban
  • Eptifibatide
  • Abciximab